The complexity of MS necessitates a holistic approach when it comes to research – a comprehensive strategy that can propel knowledge, better treatments, health care policies, and new disease management therapies forward, faster.
We are a driving force of MS research and treatment to stop disease progression, restore function, and end MS forever.
The National MS Society supports and funds research activities spanning ALL research stages, including early discovery research, translational research that brings promising ideas forward into actual therapeutic solutions for testing, and clinical trials. Our unique approach drives the pursuit of all promising avenues that can impact those living with multiple sclerosis.
We drive progress through a comprehensive approach to research review and funding, including a variety of Society programs, and our Fast Forward initiative, focused on advancing the transition of promising new therapies to rapid commercial development and understanding mechanisms underlying the disease so that it can be cured.
Recent Research News
May 24, 2013
In proclaiming May as National Mental Health Awareness Month, President Barack Obama sought to “shine a light” on the mental health problems experienced by tens of millions of Americans. Emotional changes may be a major concern for people with MS. Clinical psychologist David Rintell, EdD (Brigham & Women’s Hospital, Boston) addresses these issues with people with MS in his practice, and has been funded by the National MS Society’s Health Care Delivery and Policy Research (HCDPR)program to study ways to help enhance mental health to people with MS.
May 22, 2013
Summary: Investigators nationwide are recruiting 60 people with all types of MS for a phase I study to determine the safety and tolerability of rHIgM22, an experimental antibody. The study is funded by Acorda Therapeutics, Inc.
May 21, 2013
Biogen Idec announced that a phase III study of peginterferon beta-1a, injected under the skin either every two or four weeks, reduced the relapse rate significantly more than placebo in a study of 1500 people with relapsing MS, reaching the primary goal of the study. Peginterferon is a new formulation of the interferon beta-1a molecule which enables it to maintain effects in the body for longer periods of time. More data from this ongoing study, also called the ADVANCE study, will be presented at the American Academy of Neurology Annual Meeting in March. According to a press release, the company is planning to file for regulatory approval in the United States and European Union in 2013.
more research news